Target intelligence / Profile preview

5-hydroxytryptamine receptor 3 (5-HT3) and 5-hydroxytryptamine receptor 4 (5-HT4) (5-HT3/4)

Target
5-HT3/4
Molecular classification
Ion channel, G protein-coupled receptor, Receptor
01

Overview

The 5-hydroxytryptamine (5-HT) system, specifically the 5-HT3 and 5-HT4 receptors, plays a critical role in regulating gastrointestinal (GI) function and the central nervous system (IUPHAR/BPS Guide to Pharmacology, 2024). The 5-HT3 receptor is a unique member of the serotonin receptor family as it is a ligand-gated ion channel, primarily responsible for rapid excitatory neurotransmission and the mediation of the emetic reflex (UniProt P46098). In contrast, the 5-HT4 receptor is a G protein-coupled receptor that stimulates adenylyl cyclase, leading to increased acetylcholine release and enhanced GI motility (UniProt Q13639). These receptors are major therapeutic targets for managing GI disorders; 5-HT3 antagonists like ondansetron are gold-standard treatments for chemotherapy-induced nausea and vomiting (StatPearls, 2023). 5-HT4 agonists like prucalopride are used as prokinetic agents for chronic constipation and irritable bowel syndrome (PubMed, 2022). Pharmacological modulation of these receptors requires careful management due to potential side effects, including QT prolongation and cardiovascular risks (FDA, 2020). Together, these receptors represent distinct but complementary pathways for controlling enteric nervous system activity and visceral sensation.

Other names
Serotonin receptor 3Serotonin receptor 4HTR3HTR45-HT3R5-HT4R5-hydroxytryptamine system
02

Mechanism of action

5-HT3 receptor antagonism (blocking ligand-gated cation channels on vagal afferents) and 5-HT4 receptor agonism (stimulating Gs-coupled receptors to increase cAMP and acetylcholine release in the enteric nervous system).

03

Biological functions

Signal transductionGastrointestinal motilityEmesisNeurotransmission
04

Disease associations

Irritable bowel syndromeChemotherapy-induced nausea and vomitingChronic constipationGastroparesis
05

Safety considerations

QT interval prolongationIschemic colitisCardiovascular adverse eventsSerotonin syndrome
06

Interacting drugs

Ondansetron

7 more in the full profile.

07

Biomarkers

Gastric emptying timeStool frequencyBristol Stool Scale score

Beyond the preview

Go deeper on 5-hydroxytryptamine receptor 3 (5-HT3) and 5-hydroxytryptamine receptor 4 (5-HT4) (5-HT3/4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-hydroxytryptamine receptor 3 (5-HT3) and 5-hydroxytryptamine receptor 4 (5-HT4) (5-HT3/4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call